CuraSen joins the international community in honoring the 10 million people living worldwide with Parkinson’s disease, a neurodegenerative disorder that affects predominately the dopamine-producing neurons in the brain. Parkinson’s causes both motor symptoms, such as tremor, muscle stiffness and impaired gait, and non-motor-symptoms, including declines in memory, attention, social cognition and executive functioning skills. Our Phase 2 compounds, CST-103 and CST-2032, have shown robust improvements in Parkinson’s and Alzheimer’s patients with mild cognitive impairment by restoring adrenergic function to the brain. We look forward to testing these compounds in longer, larger studies later this year. www.curasen.com/pipeline/. To learn more about Parkinson’s, please visit: https://lnkd.in/exBwUTwQ. #Parkinson's#Phase2clinicaltrials#mildcognitiveimpairment#MCI
CuraSen Therapeutics, Inc.
生物技术研究
San Carlos，California 833 位关注者
Targeting neurodegeneration with novel science and treatments so patients can THINK, AGAIN
关于我们
It’s time to think again about therapies for neurodegenerative disease. At CuraSen, we are targeting neurodegeneration with novel science and treatments so patients can THINK, AGAIN. CuraSen Therapeutics, Inc. is a privately funded biopharmaceutical company pursuing development of novel treatments for neurodegenerative diseases, including Parkinson’s disease and Alzheimer’s disease, as well as several orphan indications. Millions of patients and their families are burdened by these diseases, and the numbers continue to grow annually with the aging population. At CuraSen, we are rethinking the therapeutic approach to treatment of neurodegenerative diseases—and advancing a concept based on restoring a key functionality to a pathway lost early in the degenerating brain. This pathway emanates from the locus coeruleus (LC), site of the earliest pathology seen in these diseases – perhaps the ‘hypocenter’ of neurodegeneration. We began clinical testing of our hypothesis in 2019 using established drugs from other therapeutic areas, which has informed our development program and helped advance our first new chemical entity, CST-2032, to the clinic in September 2020. CuraSen has assembled an impressive team, deeply experienced in the neuroscience, pharmacology and clinical development core to its approach, as well as top tier investor backing, including New Leaf Venture Partners, Longitude Capital, funds managed by Tekla Capital Management LLC, Alta Partners, Johnson & Johnson Innovation – JJDC, Inc. (JJDC), and Pappas Capital.
- 网站
-
https://www.curasen.com
CuraSen Therapeutics, Inc.的外部链接
- 所属行业
- 生物技术研究
- 规模
- 11-50 人
- 总部
- San Carlos，California
- 类型
- 私人持股
- 创立
- 2017
- 领域
- Parkinson’s Disease, Alzheimer’s Disease、Locus Coeruleus、Neurodegeneration、Neuroinflammation、Neurometabolism和Cerebral Blood Flow
地点
-
主要
获取路线
930 Brittan Ave
#306
US，California，San Carlos，94070
CuraSen Therapeutics, Inc.员工
动态
-
?? New data from a phase 2a trial assessing CuraSen Therapeutics, Inc.'s combination adrenergic activator showed significant improvement with the treatment across several cognitive domains in patients with #MCI or mild dementia from either #AD or #PD. #ADPD2024 AD/PD - Advances in Science & Therapy https://lnkd.in/ejYwQD2g
-
Attending the AD/PD conference in Lisbon this week? Our chief medical officer, Gabriel Vargas, MD, PhD, will give an oral presentation of our impressive Phase 2a data in Alzheimer’s and Parkinson’s disease patients this Sat March 9 at 17:25 UTC. CuraSen’s combination adrenergic activator, CST-2032/CST-107, achieved statistically and clinically important effects across several cognitive domains, such as memory, attention, executive function, facial recognition and impulse control — areas known to be impacted by adrenergic function. We plan to initiate longer studies with CST-2032/CST-107 in AD/PD patients with MCI later this year. https://lnkd.in/ghSxqppm #AD#PD#MCI
-
-
We’re looking forward to sharing encouraging Phase 2 data in patients with Alzheimer’s disease with our proprietary combination treatment (CST-2032/CST-107) at the Clinical Trials in Alzheimer's Disease conference this week in Boston. Dr. John Harrison, a cognition expert and associate professor at the Alzheimer Center at Amsterdam’s VU medical center, will present our late-breaking abstract (#PO34):?“Combination Treatment of a Novel β2-Adrenoceptor Agonist, CST-2032, and Nadolol Improves Cognitive Measures in Patients with Alzheimer’s Disease. #CTAD #Alzheimers #Phase2 #dementia #MCI #CTAD# See our website for the poster - www.curasen.com/news.
News | CuraSen
https://www.curasen.com